|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 5 (March 1), 1999:
pp. 1732-1737
Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High
Risk of Disease Progression in Early, Nonsmoldering Chronic
Lymphocytic Leukemia
Michael Hallek,
Irmgard Langenmayer,
Christoph Nerl,
Wolfgang Knauf,
Hermann Dietzfelbinger,
Dagmar Adorf,
Marianne Ostwald,
Raymonde Busch,
Ingrid Kuhn-Hallek,
Eckhard Thiel, and
Bertold Emmerich
From the Medizinische Klinik, Abteilung für Hämatologie
und Onkologie, Klinikum Innenstadt,
Ludwig-Maximilians-Universität München; Städtisches
Krankenhaus München Schwabing; I. Medizinische Klinik und
Poliklinik, Abteilung für Hämatologie und Onkologie,
Institut für Medizinische Statistik und Epidemiologie, Technische
Universität München; Medizinische Klinik III mit
Schwerpunkt Hämatologie, Onkologie und Transfusionsmedizin,
Universitätsklinikum Benjamin Franklin der Freien
Universität Berlin, Germany.
Chronic lymphocytic leukemia (CLL) shows a remarkably heterogeneous
clinical outcome; survival ranges from several months in advanced
stages to more than 10 years in early stages. The Binet and Rai staging
systems distinguish three major prognostic subgroups, but do not
accurately predict the individual risk of disease progression in early
CLL (Binet stage A or Rai stage 0 to II). Because most newly diagnosed
CLL patients present with early disease, it seems desirable to search
for additional prognostic factors to identify early CLL patients at
high risk of rapid progression. It has been shown that elevated serum
thymidine kinase (s-TK) levels predict disease progression in CLL.
Therefore, this study aimed to assess the prognostic value of s-TK in
122 previously untreated patients with Binet stage A CLL (mean age ± SD, 58.7 ± 8.5 years). In univariate analyses, 18 of the 22 parameters investigated predicted progression-free survival (PFS). In a
stepwise multiple regression analysis, only three parameters provided
independent prognostic information on PFS: s-TK greater than 7.1 U/L;
presence of lymphadenopathy; and white blood cell (WBC) count greater
than 75,000/µL. When added to the classification of smoldering versus nonsmoldering CLL, s-TK levels separated two groups within the group of
nonsmoldering stage A patients: patients with s-TK values greater than
7.1 U/L had a median PFS of 8 months, whereas patients with s-TK values  7.1 U/L expected a much longer PFS (49 months; P < .001),
similar to smoldering CLL (42 months). The results demonstrate that
s-TK is a prognostic parameter that adds independent prognostic
information to the definitions of smoldering and nonsmoldering CLL in
Binet stage A.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al.
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
J. Clin. Oncol.,
August 20, 2009;
27(24):
3994 - 4001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER
Chronic Lymphocytic Leukaemia
Anticancer Res,
February 1, 2009;
29(2):
605 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Blood,
June 15, 2008;
111(12):
5446 - 5456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tsimberidou, S. Wen, S. O'Brien, P. McLaughlin, W. G. Wierda, A. Ferrajoli, S. Faderl, J. Manning, S. Lerner, C. V. Mai, et al.
Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center
J. Clin. Oncol.,
October 10, 2007;
25(29):
4648 - 4656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Binet, F. Caligaris-Cappio, D. Catovsky, B. Cheson, T. Davis, G. Dighiero, H. Dohner, M. Hallek, P. Hillmen, M. Keating, et al.
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
Blood,
February 1, 2006;
107(3):
859 - 861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Abbott
Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment
Oncologist,
January 1, 2006;
11(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Marasca, R. Maffei, M. Morselli, P. Zucchini, I. Castelli, S. Martinelli, M. Fontana, S. Ravanetti, M. Curotti, G. Leonardi, et al.
Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia
J. Mol. Diagn.,
November 1, 2005;
7(5):
566 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Oppezzo, Y. Vasconcelos, C. Settegrana, D. Jeannel, F. Vuillier, M. Legarff-Tavernier, E. Y. Kimura, S. Bechet, G. Dumas, M. Brissard, et al.
The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia
Blood,
July 15, 2005;
106(2):
650 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ohrvik, M. Lindh, R. Einarsson, J. Grassi, and S. Eriksson
Sensitive Nonradiometric Method for Determining Thymidine Kinase 1 Activity
Clin. Chem.,
September 1, 2004;
50(9):
1597 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt and T. G. Call
Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia
Mayo Clin. Proc.,
March 1, 2004;
79(3):
388 - 398.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, S. M. Geyer, and N. E. Kay
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL
Blood,
February 15, 2004;
103(4):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2004;
2004(1):
163 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ghia, G. Guida, S. Stella, D. Gottardi, M. Geuna, G. Strola, C. Scielzo, and F. Caligaris-Cappio
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression
Blood,
February 15, 2003;
101(4):
1262 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Oscier, A. C. Gardiner, S. J. Mould, S. Glide, Z. A. Davis, R. E. Ibbotson, M. M. Corcoran, R. M. Chapman, P. W. Thomas, J. A. Copplestone, et al.
Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
Blood,
July 30, 2002;
100(4):
1177 - 1184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug, S. Rothenfusser, G. Meinhardt, B. Emmerich, S. Endres, and G. Hartmann
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
J. Leukoc. Biol.,
July 1, 2002;
72(1):
83 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Hamblin, J. A. Orchard, R. E. Ibbotson, Z. Davis, P. W. Thomas, F. K. Stevenson, and D. G. Oscier
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
Blood,
February 1, 2002;
99(3):
1023 - 1029.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2002;
2002(1):
193 - 213.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Del Poeta, L. Maurillo, A. Venditti, F. Buccisano, A. M. Epiceno, G. Capelli, A. Tamburini, G. Suppo, A. Battaglia, M. I. Del Principe, et al.
Clinical significance of CD38 expression in chronic lymphocytic leukemia
Blood,
November 1, 2001;
98(9):
2633 - 2639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, et al.
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
Blood,
September 15, 1999;
94(6):
1840 - 1847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
